Notably, pairing gene therapies with immune checkpoint inhibitors, which block proteins like PD-1 and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) to restore immune activity, has significantly enhanced immune responses in cancers like melanoma and lung cancer (108, 109). This evidence concerns the gene CTLA4 and lung cancer.